PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.29%
Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
27.06%
Operating income growth at 75-90% of AXSM's 35.57%. Bill Ackman would demand a plan to enhance operating leverage.
-304.05%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-302.06%
Negative EPS growth while AXSM is at 20.49%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-288.66%
Negative diluted EPS growth while AXSM is at 20.49%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.11%
Share reduction more than 1.5x AXSM's 1.17%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.68%
Diluted share count expanding well above AXSM's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
56.08%
OCF growth above 1.5x AXSM's 25.25%. David Dodd would confirm a clear edge in underlying cash generation.
56.11%
FCF growth above 1.5x AXSM's 25.25%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18524.76%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-17391.51%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-1778.39%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-42866.91%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-15208.07%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-5247.61%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4590.00%
10Y equity/share CAGR above 1.5x AXSM's 360.64%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
1682.71%
Positive 5Y equity/share CAGR while AXSM is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
1405.22%
3Y equity/share CAGR above 1.5x AXSM's 280.02%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Asset growth above 1.5x AXSM's 7.23%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
247.25%
BV/share growth above 1.5x AXSM's 35.76%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-50.51%
We’re deleveraging while AXSM stands at 2.81%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-53.09%
Our R&D shrinks while AXSM invests at 10.62%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.56%
SG&A declining or stable vs. AXSM's 7.86%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.